Tina Thethi, MD
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1295849552
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $195,288 of the $244,002 with a category attached, or 80.0%. Lilly USA, LLC accounts for 62.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $85,381, 2.7 times the $31,462 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $893.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$153K
- Novo Nordisk$67K
- Bayer$24K
- Abbott$319
- Sanofi-aventis U.S. LLC$243
- Janssen Scientific Affairs, LLC$127
- plus $123 from 6 others
Across 1,489 payments — averaging $2364.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.2M
- Novo Nordisk AS$246K
- Bayer$109K
- Novo Nordisk$9K
What the payments were for
- Consulting fees$26,11311%
- Speaking & faculty fees$195,28880%
- Travel & lodging$17,9087%
- Food & beverage$4,6602%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 152 | $152,739 |
| Novo Nordisk | 60 | $66,913 |
| Bayer | 46 | $23,536 |
| Abbott | 2 | $319 |
| Sanofi-aventis U.S. LLC | 5 | $243 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Dexcom, Inc. | 1 | $35 |
| Renalytix AI, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $22 |
| Merck | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Corcept Therapeutics | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$244,002 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $121,097 |
| MounjaroTirzepatide | 57 | $84,133 |
| TrulicityDulaglutide | 42 | $60,845 |
| JardianceEmpagliflozin | 36 | $50,346 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $38,220 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $25,287 |
| RybelsusSemaglutide | 12 | $15,405 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $9,618 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $5,625 |
| Saxagliptin Hcl | 11 | $973 |
| Levothyroxine Sodium | 96 | $862 |
| Metformin Hcl ErMetformin Hcl | 25 | $565 |
| Rosuvastatin Calcium | 16 | $215 |
| Glipizide ErGlipizide | 11 | $151 |
| Metformin Hcl | 22 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $152,739 | $144,97899 claims |
| Novo NordiskOzempic, Rybelsus | $66,913 | $136,502112 claims |
| Boehringer IngelheimJardiance | $22 | $50,34636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Orlando
- Damon TantonOrlando$1.2M
- Richard PratleyOrlando$735K
- Hanford YauOrlando$489K
- Steven SmithOrlando$390K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.